S-Nitrosoglutathione

Summary

S‑Nitrosoglutathione (GSNO) is an endogenous S‑nitrosothiol that serves as a carrier and donor of nitric oxide (NO). It is being investigated for its broad‑spectrum antimicrobial properties, its role in redox signalling, and as a potential therapeutic NO donor in respiratory and wound‑healing applications. Current research focuses on incorporating GSNO into biomaterials, nano‑formulations, and inhalation therapies to exploit its antimicrobial activity while maintaining biocompatibility.

Mechanism of Action

GSNO stores NO in a nitroso bond that can be cleaved enzymatically or spontaneously, liberating NO and transferring the nitroso group to thiol residues on proteins (S‑nitrosylation). These reactions modulate vascular tone, immune responses and bacterial viability. Cellular levels are controlled by GSNO reductase, which reduces GSNO back to glutathione, and by transport mechanisms that often require extracellular cysteine or cystine to facilitate uptake. Consequently, GSNO exerts effects through both classic NO signalling (e.g., guanylate cyclase activation) and direct S‑nitrosylation of target proteins.

What the Research Shows

Published literature on GSNO consists mainly of review articles that synthesize pre‑clinical and biochemical data. GSNO is described as a potent, broad‑spectrum antibacterial agent whose activity is retained when incorporated into polymeric or metallic biomaterials, offering enhanced anti‑infective performance without compromising cell compatibility (Mater Today Bio 2022). Biochemical reviews outline its dual mode of action—release of nitric oxide and protein S‑nitrosylation—and its central role in cellular redox signalling (Biochim Biophys Acta 2013; Free Radic Biol Med 2005). Transport studies indicate that GSNO entry into cells often depends on extracellular cysteine/cystine rather than direct amino‑acid transport. Plant‑science work highlights GSNO reductase and thioredoxin as regulators of specificity in NO signalling (J Exp Bot 2018). In respiratory disease, increased GSNO reductase activity is a hallmark of certain asthma phenotypes (Biochim Biophys Acta 2011). Finally, nano‑ and micro‑encapsulation strategies have been reviewed to overcome GSNO’s rapid degradation and to enable controlled release for therapeutic use (Nanomaterials 2023). No human clinical trials were identified in the cited abstracts.

Reported Benefits

GSNO’s principal advantage lies in its ability to deliver nitric oxide in a controlled fashion, providing broad‑spectrum antibacterial effects that are less prone to resistance development. When embedded in biomaterials, it can prevent bacterial colonisation of implants and wound dressings while supporting mammalian cell viability. Its endogenous nature suggests a favorable biocompatibility profile compared with synthetic NO donors. Additionally, modulation of GSNO levels has been linked to airway inflammation markers, raising the possibility of diagnostic or therapeutic relevance in asthma sub‑types.

Limitations of the Evidence

Despite promising in‑vitro activity, GSNO is chemically unstable, rapidly decomposing to release NO and glutathione, which hampers its practical use. Effective delivery requires protective formulations, yet current nano‑encapsulation approaches face low loading efficiency and burst‑release phenomena. Evidence for therapeutic benefit remains limited to laboratory and animal models; no clinical efficacy data have been reported. Moreover, the mechanisms governing cellular uptake and metabolism are incompletely understood, and the impact of chronic exposure on systemic nitrosative stress has not been fully evaluated.

Safety Considerations

GSNO is an endogenous molecule and is generally well tolerated in cell‑culture studies, showing minimal cytotoxicity at concentrations that achieve antimicrobial activity. However, as a nitric oxide donor, excessive levels could theoretically cause vasodilation, hypotension, or nitrosative damage, especially if release is uncontrolled. The lack of human trial data means that a comprehensive safety profile, including potential allergic or oxidative effects, has not been established. Caution is therefore advised when advancing GSNO‑based therapies toward clinical use.

How It Is Administered

GSNO can be administered by inhalation, intranasal spray, intravenous infusion, or topical application, depending on the intended target tissue. Because the free compound degrades rapidly, research formulations often embed GSNO in polymeric matrices, liposomes, or other nano‑carriers to protect it and enable sustained release at the site of action.

Routes of Administration

Goals & Uses

• Pulmonary vasodilation in persistent pulmonary hypertension of the newborn (PPHN)Cardiovascular / PulmonaryModerate
• Systemic vasodilation in hypertensive crisisCardiovascularLow
• anti‑inflammatoryTherapeuticModerate
• NO donationVascularHigh
• NeuroprotectionNeurologyModerate
• Wound healingDermatologicLowTissue repair and wound healing
• Bronchodilation / airway relaxationPulmonaryModerate
• Platelet inhibition / antithrombotic effectHematologyModerate

Contraindications

• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Phosphodiesterase-5 inhibitor use (e.g., sildenafil)Drug InteractionHigh
• Methemoglobinemia or glucose-6-phosphate dehydrogenase deficiencyHematologicModerate
• Severe hypotensionCardiovascularHigh

Adverse Effects

• Tachycardia (reflex)CardiovascularUncommon
• MethemoglobinemiaHematologicUncommon
• HeadacheNeurologicCommonPain in the head or upper neck
• HypotensionCardiovascularCommonLow blood pressure
• FlushingVascularCommonWarmth and redness of the skin

Drug Interactions

• Sildenafil / PDE5 inhibitorsHigh
• GSNO reductase (GSNOR) inhibitorsModerate
• Antihypertensive agentsModerate
• Other NO donors (e.g., nitroglycerin)High
• Phosphodiesterase‑5 inhibitorsModerate
• Antiplatelet agents / anticoagulantsModerate

Population Constraints

• Pediatric patientsAgeRelative
• Premature neonatesPediatricRelative
• Pregnant womenReproductiveRelative
• Elderly with cardiovascular diseaseComorbidityRelative
• Patients with renal or hepatic impairmentOrgan FunctionRelative

Regulatory Status

• European UnionUnapprovedNot authorized for medicinal use
• United StatesUnapprovedConsidered a research chemical
• United KingdomUnapprovedNo clinical approval

Not approved for therapeutic use; classified as a research chemical in most jurisdictions.

Evidence & Sources

• Roles and current applications of S-nitrosoglutathione in anti-infective biomaterials
  Journal ArticleModerateQian H, et al.2022-01-01T00:00:00.000000Z
• S-nitrosoglutathione
  Journal ArticleModerateBroniowska KA, Diers AR, Hogg N2013-01-01T00:00:00.000000Z
• S-Nitrosothiols: cellular formation and transport
  Journal ArticleModerateZhang Y, Hogg N2005-01-01T00:00:00.000000Z
• Specificity in nitric oxide signalling
  Journal ArticleModerateUmbreen S, et al.2018-01-01T00:00:00.000000Z
• The biochemistry of asthma
  Journal ArticleModerateGaston B2011-01-01T00:00:00.000000Z
• A Mini Review of S-Nitrosoglutathione Loaded Nano/Micro-Formulation Strategies
  Journal ArticleModerateMing H, et al.2023-01-01T00:00:00.000000Z

Frequently Asked Questions